全文获取类型
收费全文 | 5023篇 |
免费 | 311篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 22篇 |
儿科学 | 190篇 |
妇产科学 | 123篇 |
基础医学 | 514篇 |
口腔科学 | 138篇 |
临床医学 | 424篇 |
内科学 | 1673篇 |
皮肤病学 | 99篇 |
神经病学 | 386篇 |
特种医学 | 169篇 |
外国民族医学 | 1篇 |
外科学 | 564篇 |
综合类 | 53篇 |
一般理论 | 1篇 |
预防医学 | 189篇 |
眼科学 | 25篇 |
药学 | 375篇 |
中国医学 | 8篇 |
肿瘤学 | 398篇 |
出版年
2023年 | 28篇 |
2021年 | 105篇 |
2020年 | 52篇 |
2019年 | 106篇 |
2018年 | 130篇 |
2017年 | 97篇 |
2016年 | 102篇 |
2015年 | 90篇 |
2014年 | 152篇 |
2013年 | 208篇 |
2012年 | 240篇 |
2011年 | 251篇 |
2010年 | 161篇 |
2009年 | 153篇 |
2008年 | 204篇 |
2007年 | 248篇 |
2006年 | 245篇 |
2005年 | 234篇 |
2004年 | 202篇 |
2003年 | 193篇 |
2002年 | 191篇 |
2001年 | 164篇 |
2000年 | 171篇 |
1999年 | 151篇 |
1998年 | 60篇 |
1997年 | 49篇 |
1996年 | 50篇 |
1995年 | 59篇 |
1994年 | 60篇 |
1993年 | 56篇 |
1992年 | 112篇 |
1991年 | 66篇 |
1990年 | 80篇 |
1989年 | 78篇 |
1988年 | 70篇 |
1987年 | 72篇 |
1986年 | 58篇 |
1985年 | 67篇 |
1984年 | 48篇 |
1983年 | 58篇 |
1982年 | 30篇 |
1981年 | 22篇 |
1980年 | 22篇 |
1979年 | 36篇 |
1978年 | 26篇 |
1977年 | 20篇 |
1976年 | 22篇 |
1975年 | 31篇 |
1974年 | 30篇 |
1970年 | 20篇 |
排序方式: 共有5352条查询结果,搜索用时 46 毫秒
1.
Saleh A Alqahtani Massimo G Colombo 《World journal of gastrointestinal oncology》2021,13(12):2038-2049
Globally, hepatocellular carcinoma (HCC) is a frequently diagnosed malignancy with rapidly increasing incidence and mortality rates. Unfortunately, many of these patients are diagnosed in the advanced stages when locoregional treatments are not appropriate. Before 2008, no effective drug treatments existed to prolong survival, until the breakthrough multi-tyrosine kinase inhibitor (TKI) sorafenib was developed. It remained the standard treatment option for advanced HCC for 10 years, with a battery of other candidate drugs in clinical trials failing to produce similar efficacy results. In 2018, the REFLECT trial introduced another multi-TKI, lenvatinib, which has non-inferior overall survival compared with sorafenib. Thus, offering patients and their treating physicians two effective treatment options. Recently, immunotherapy-based drugs, such as atezolizumab and bevacizumab, have shown promising results in patients with unresectable HCC. This review summarizes clinical trial and real-world data studies of sorafenib and lenvatinib in patients with unresectable HCC. We offer guidance on the optimal choice between the two treatments and discuss the potential of immunotherapy-based combination; when more data become available, this will likely make the choice between sorafenib and lenvatinib somewhat obsolete. 相似文献
2.
3.
Petry Vanessa Bonadio Renata Colombo Cagnacci Allyne Queiroz Carneiro Senna Luiz Antonio Leite Campos Roberta do Nascimento Galvão Cotti Guilherme Cutait Hoff Paulo M. Fragoso Maria Candida Barisson Villares Estevez-Diz Maria del Pilar 《Familial cancer》2020,19(1):47-53
Familial Cancer - The risk of radiotherapy-induced malignancies (RIMs) is a concern when treating Li–Fraumeni syndrome (LFS) or Li–Fraumeni Like (LFL) patients. However, the type of... 相似文献
4.
5.
6.
Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines
Alice Iezzi Elisa Caiola Marika Colombo Mirko Marabese Massimo Broggini 《American journal of cancer research》2020,10(12):4488
Despite the impressive results obtained in the preclinical setting, all the inhibitors targeting two central cascades in cancer, the PI3K/akt/mTOR and the KRAS/MEK/ERK pathways, have shown, apart from very few exceptions, disappointing efficacy when translated to the clinic. One of the main reasons of their clinical failure seems to be the lack of a clear molecular determinant of response to these drugs. In this study, we tried to address this point by evaluating the cytotoxic activity of different inhibitors targeting the two pathways at different levels in a panel of ten NSCLC cell lines harboring alterations in PI3K, KRAS or both. We were not able to highlight a correlation between the presence of KRAS and PI3K mutations and a specific sensitivity to the different drugs used. Molecular analyses performed after equimolar treatments showed that, independently from the entity of the response, the drugs are able to modulate the activation of their targets. Interestingly, we found that p53 mutational status separates the cell lines according to their sensitivity to PI3K pathway inhibitors treatments. The alterations considered in the PI3K/akt/mTOR and in the KRAS/MEK/ERK pathways in the different NSCLC cell lines are not sufficient to drive treatment choice but rather p53 status is a potential biomarker for the activity of this class of drugs. 相似文献
7.
Masha Y. Ivanova Thomas M. Achenbach Leslie A. Rescorla Lori V. Turner Julie A. Dumas Vera Almeida Meltem Anafarta-Sendag Ieva Bite Dorret I. Boomsma J. Carlos Caldas John W. Capps Yi-Chuen Chen Paola Colombo Margareth da Silva Oliveira Anca Dobrean Nese Erol Alessandra Frigerio Yasuko Funabiki Reda Gedutienė Halldór S. Guðmundsson Min Quan Heo Young Ah Kim Tih-Shih Lee Manuela Leite Jianghong Liu Jasminka Markovic Monika Misiec Marcus Müller Kyung Ja Oh Verónica Portillo-Reyes Wolfgang Retz Sandra B. Sebre Shupeng Shi Sigurveig H. Sigurðardóttir Roma Šimulionienė Elvisa Sokoli Tanja Tomasevic Jacqueline M. Vink Ewa Zasępa 《International journal of geriatric psychiatry》2020,35(5):525-536
8.
9.
Alessandro Beneduce MD Cristina Capogrosso MD Francesco Moroni MD Francesco Ancona MD Giulio Falasconi MD Luigi Pannone MD Stefano Stella MD Giacomo Ingallina MD Francesco Melillo MD Marco Bruno Ancona MD Vittorio Romano RT Anna Palmisano MD Azeem Latib MD Antonio Colombo MD Matteo Montorfano MD Antonio Esposito MD Eustachio Agricola MD 《Echocardiography (Mount Kisco, N.Y.)》2020,37(12):2071-2081
10.